



## Universal Opioid Utilization Management Initiative

The State and the three managed care entities (MCEs) that service Indiana Medicaid members (both HIP and HCC) have developed utilization management criteria to address the growing epidemic of opioid misuse, abuse, and addiction. Fee-For-Service Medicaid (OptumRx) has had these new opioid UM criteria in place for some weeks and the Indiana Medicaid MCEs are following suit in cooperation with the State.

This universal opioid UM initiative is being rolled out in a phased approach and will be complete by 1/1/2017.

MDwise will administer opioid UM in three phases:

- Phase 1 effective 10/17/2016
  - Applies to new users of short-acting opioids (defined as those who do not have utilization in a 45 day lookback period); members with claims history within the 45 day lookback period are grandfathered
  - Limits total daily dose of short-acting opioids to 60MED
  - Maximum of 7 days supply per dispensing
  - Maximum of 14 days supply in a 45 day timeframe
  - PA would only be required to go beyond these limits
- Phase 2 effective 11/16/2016
  - Limits members to no more than one long-acting and one short-acting opioid concurrently
  - Members with claims history of use of more than one short-acting and one long-acting will be allowed continuity of care for 6 months in order to make appropriate adjustments to therapy or submit for PA
- Phase 3 effective 11/28/2016
  - PA required for all new starts of long-acting opioids
  - Members with claims history of existing long-acting opioids will be grandfathered

For all phases, a PA process will allow for medical necessity review. Exceptions will be granted for specific populations (e.g., post-surgical pain, cancer, sickle cell disease, palliative care) under certain circumstances.

MDwise has created an opioid-specific medication request form (MRF) to aid prescribers in obtaining PA for their patients. Providers may access this form on our website at <http://www.mdwise.org/for-providers/forms/pharmacy>.